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Defects of the oxidative ATP production pathway lead to an amazing variety of disease phenotypes, ranging from childhood encephalo-
myopathies to hereditary tumor formation. A key enzyme of tricarboxylic cycle, fumarate hydratase (FH), is involved in encephalopathies, but
also in leiomyoma formation, and occasionally also in various types of cancer. MELAS (mitochondrial encephalomyopathy, lactic acidosis and
stroke-like episodes) and NARP (neuropathy ataxia retinitis pigmentosa) are progressive neurological disorders, caused by mitochondrial DNA
mutations and respiratory chain (RC) deficiency. These diseases lead to disability and premature death, but not to tumorigenesis. We studied the
cellular consequences of FH and RC deficiencies, aiming to identify general responses to energy metabolism defect and those specific for
FH-deficiency, suggestively connected to tumorigenesis. Unlike in RC deficiency, the FH-deficient diploid human fibroblasts showed no signs of
oxidative stress, but had a reduced redox state with high glutathione levels. The cytoplasmic FH isoform, previously described, but with an unknown
function, was completely lacking in all FH-deficient lines. Fumaratewas increased in two of our FH-lines, but accumulation of HIF-1αwas not detected.
Glycolysis was induced in both MELAS and in FH-deficiency. Accumulation of fumarate in primary fibroblasts did not activate a hypoxia response,
suggesting that hypoxia activation due to fumarate accumulationmay be a tissue-specific response. The lack of cytoplasmic form of FH and the reduced
redox environment were typical for all FH-mutant lines, and their role in FH-related tumorigenesis requires further attention.
© 2008 Elsevier B.V. All rights reserved.Keywords: Mitochondria; Fumarate hydratase; Redox state; Respiratory chain defect1. Introduction
The mitochondrial tricarboxylic acid cycle (TCA, also
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doi:10.1016/j.bbadis.2008.01.008enzymes, succinate dehydrogenase (SDH) and fumarate
hydratase (FH) have been identified as tumor suppressors [1–
5]. Dominant mutations of succinate dehydrogenase subunits B,
C and D are associated with development of pheochromocy-
tomas and paragangliomas, and FH defects predispose to
hereditary leiomyomatosis and renal cell cancer syndrome
(HLRCC, OMIM #605839), as well are occasionally associated
with ovary adenocarcinomas, Leydig cell tumors and cerebral
cavernomas [5–8]. Autosomal recessive defects of FH and SDH
result in devastating infantile encephalopathies [9], similar to
those caused by recessive mutations of the mitochondrial
respiratory chain (RC) and by some mitochondrial DNA
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cellular ATP, it is likely that the energetic defect underlies the
severe childhood encephalopathies. However, tumor predis-
position is specific to FH and SDH mutations, not a feature of
the relative common RC defects.Fig. 1. Fumarate hydratase protein levels and localization in fibroblast lines. (A) M
controls were analyzed by Western blot, with FH-specific antibody. All cell lines sh
mitochondrial marker shows equal loading. The bands of FH and SDH were quantifie
cytoplasmic extracts (10 µg protein/well), also showing β-actin as a loading control.
lack of mitochondria in the extracts. The bands of FH and β-actin were quantified aga
protein) inwhole cells. Significant changes aremarked: ⁎⁎(pb0.01) or ⁎⁎⁎(pb0.001).
line controls 1–3; all other values represent the average±sd for each cell line. Abbrevia
FH-2, Q376P homozygote; FH-3, compound heterozygote InsK477/R233H; FH
dehydrogenase subunit A; MELAS, fibroblasts from a patient with mutation T3271C (
WCE, whole cell extract.Germ line heterozygosity for FHmutations underliesHLRCC,
and the tumors are generated after somatic loss of the normal
allele [10]. The underlying primary events of tumorigenesis have
remained elusive. Both FH and SDH deficient tumors show
induction of hypoxia pathway [11–13], which has been suggesteditochondrial extracts (10 µg protein/well) of FH patient fibroblast samples and
ow almost completely the mature processed FH form of ~48 kDa. SDHA as a
d against the background using Image J software. (B) Same analysis as in A, with
FH1–4 lines lack the mature 48 kDa isoform in the cytoplasm. SDHA shows the
inst the background using Image J software. (C) Fumarate concentration (µM/mg
The controls represent the average±sd of the values for three individual fibroblast
tions: FH-1, fumarate dehydratase-deficient patient sample, E362Q homozygote;
-4, compound heterozygote with delV387+Q386H/P369S; SDHA, succinate
~80%mutated mtDNA); NARP, sample with T8993C (~90%mutated mtDNA);
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to growth of several tumor types [15]. However, its role in
primary tumorigenesis in FH-deficiency remains still suggestive.
We studied the effects of FH and RC deficiencies on cellular
metabolism, hypoxia response, and redox metabolism. Both con-
ditions result in reduced ATP production, but only FH-deficiency
is associatedwith tumorigenesis. Both common energy-deficiency
responses and FH-specific changes were identified, and their
putative roles in FH-related tumor formation are discussed.
2. Results
2.1. Localization of mutant FH protein: lack of cytoplasmic
form in FH-deficiency
For the activities of mutant FH forms, please see Mater-
ials and methods. First we established whether the FH muta-Fig. 2. Energy and redox metabolism. (A) HK2 transcriptional levels were determin
levels in whole cells, measuring fluorescence intensity of dichlorofluorescein-H2O2 re
fluorescence. (D) GSH concentration, determined by HPLC of a fluorescently-deriv
concentration determined by HPLC of fluorescently-derivatized compound on whole
glutathione peroxidase 1 (GPx1) in whole cell extracts. Significant changes de
⁎⁎⁎(pb0.001). The controls represent the average±sd of the values for three individu
cell line. Samples as in Fig. 1.tions affected the protein amounts or the localization, by
cellular fractionation and Western blot analysis. Mitochon-
drial FH is translated as a ∼54 kDa precursor, which is
processed upon mitochondrial transport by cleavage of the N-
terminal targeting signal, resulting in a mature form of
48 kDa. In yeast, the mature form is distributed to both
cytoplasm and mitochondria after presequence cleavage [16].
In our cells, the mature 48 kDa form of FH was present in the
mitochondria of all the FH-deficiency (FH−), RC-deficient
and control lines (Fig. 1A), albeit in three out of four FH-lines
the amount was slightly reduced. In MELAS and NARP,
mitochondrial FH was clearly increased, which may be
compensatory for RC defect. However, the cytoplasmic FH
isoform of was present in low amounts in the FH-lines, ∼10%
of controls' level, (Fig. 1B), whereas it was readily detected in
the cytoplasmic fraction of RC-deficient lines and controls
(Fig. 1B).ed by quantitative-PCR. (B) Catalase activity in whole cell extracts. (C) H2O2
action product, normalized against control wells after subtraction of background
atized compound, in the absence of DTT, on whole cell extracts. (E) Cysteine
cell extracts. (F) The ratio of enzyme activities of glutathione reductase (GR) and
termined by the two-tailed t-test are denoted as ⁎(pb0.05), ⁎⁎(pb0.01) or
al fibroblast line controls 1–3; all other values represent the average±sd for each
Fig. 3. Accumulation of HIF-1α protein in whole cell extracts. Western blot for
HIF-1α (A) was performed with whole cell extracts (10 µg/well, except for
CoCl2-treated control, 5 µg/well). β-actin was used as loading control. Abbre-
viations as in Fig. 1.
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mutations
The mass spectrometric analysis of whole cell lysates showed
that only the FH-1 and FH-2 lines, carrying homozygote mu-
tations of FH and residual FH activities of b1% and b0.5%, had
significantly increased fumarate concentration (Fig. 1C). The
lines FH-3 and FH-4 with compound heterozygote FHmutations
(activities∼20% and∼5%, respectively), as well as theMELAS
and NARP lines, had fumarate levels similar to controls. All
other metabolite levels analyzed (malate, α-ketoglutarate, succi-
nate, citrate/isocitrate, pyruvate, 2-phospho-glycerate/3-phospho-
glycerate, glucose-1-phosphate, phosphoenolpyruvate and gly-
ceraldehyde-3-phosphate), were similar in all lines (data not
shown).Fig. 4. Growth curves of the cell lines. Cells were seeded in 96-well plates, and the
normalized for each sample for its own point zero value. Samples are as follows: co
E362Q mutation; FH-2 with homozygous Q376P mutation; FH-3 with compound het
Q386H/P369S; MELAS, cells with MELAS mutation T3271C (~80% mutated mtD2.3. Metabolic and redox state of FH- and RC-lines
Since the cellular metabolic and redox states have been as-
sociated to growth control [10,14,17], we examined the meta-
bolic status and redox state of the cells. Hexokinase (HK) is the
first regulatory point of glycolysis. HK1 and HK2 are the two
HK isoforms expressed ubiquitously or in proliferative states,
respectively. HK1 mRNA level was unchanged in FH- and RC-
deficient cells compared to controls, whereas that of HK2 was
increased 1.5–3.5-fold, in FH-deficiency, MELAS and NARP
(Fig. 2A). These results suggest similar up-regulation of glyco-
lysis in all these cell lines— a logical consequence of dysfunc-
tional oxidative energy production pathway.
We then searched for evidence for reactive oxygen species in
the cell lines. The activity of catalase was ∼30% decreased in
FH-deficient cells compared to controls, while two times higher
inMELAS (Fig. 2B). The cellular levels of H2O2, the long-lived,
membrane-crossing source of hydroxyl radical, were lower in
FH-deficiency than in controls, and in control level also in the
RC-deficient lines (Fig. 2C).
Next, we focused on the major intracellular redox buffer,
glutathione (GSH). GSH concentration was significantly higher
in FH-deficient cells than in controls, but not in the RC-
deficient lines MELAS or NARP (Fig. 2D). The mRNA levels
of both the catalytic and the modifier subunits of glutamate:
cysteine ligase, catalyzing the rate-limiting step of GSH
synthesis, were increased in FH-deficiency (1.5 to 4.5-fold fornumber of cells was estimated from the amount of ATP detected in each well,
ntrol 1–3 control fibroblasts; FH-1, FH-deficient fibroblasts with homozygous
erozygosity for InsK477/R233H; FH-4, compound heterozygosity for delV387+
NA); NARP, cells with NARP mutation T8993 (~90% mutated mtDNA).
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pb0,05). The concentration of cysteine, the limiting metabolite
for GSH synthesis was increased in FH-lines, but not in RC-
deficient lines (Fig. 2E). All these data suggest increased GSH
synthesis in FH-lines. The ratio of the activities of glutathione
peroxidase 1 and glutathione reductase tended to be lower in
FH-deficiency than in controls, and especially lower than in
MELAS; FH-1 and FH-3 showed a significantly low ratio (2F).
All these data indicate a reduced redox status and no oxidative
stress in FH-deficiency, whereas some indications for ROS in
RC-lines were detected.
2.4. No hypoxia response in FH-cells
Hypoxia-inducible factor (HIF)-1α activation and nuclear
localization have previously been associated with fumarate
accumulation and tumorigenesis. We found no activation of the
major regulator of hypoxia signalling in four FH-lines or in the
RC-cells (Fig. 3).
2.5. Growth rates unaffected by FH-deficiency
No significant difference was observed in the growth rates
of FH-deficient fibroblasts versus controls in standard culture
conditions (Fig. 4), indicating that FH-deficiency or fumarate
accumulation does not provide a growth advantage in diploid
primary cells.
3. Discussion
Knowledge on the roles of energy metabolism enzymes in
human disease has expanded during recent years from infantile
encephalopathies to neurodegeneration and tumor predisposi-
tion. Familial predisposition to tumors has so far been reported
only in association with dysfunction of two Krebs cycle en-
zymes, fumarate hydratase and succinate dehydrogenase. This
suggests a role for these enzymes in growth regulation, not
directly involved in oxidative ATP production. The primary
mechanism, how a metabolic enzyme works as tumor suppres-
sor, is still unresolved. Suggested mechanisms include fumarate
accumulation and consequent HIF-1α activation, as well as
oxidative stress [10–12,14,17–19]. We studied here the meta-
bolic consequences of FH-deficiency and RC defects, both
involved in energy production pathway. RC deficiencies have
not been found to be associated with tumor predisposition,
although they are common causes of metabolic disease.
FH has been shown to exist in two cellular compartments, the
mitochondria and the cytoplasm, in the yeast S. cerevisiae [16],
but the function of the cytoplasmic isoform is unknown in all
organisms. In yeast, one FH precursor, common to both isoforms,
is targeted to mitochondria, and the translocation is tightly
coupled with translation [16,20]. The targeting peptide is cleaved
by the mitochondrial processing peptidase, and the mature form
released partially to mitochondrial matrix, and partially to the
cytoplasm [21]. Themammalian cytoplasmic FHhas been shown
to exist in a number of previous studies [22–24], but its presence
was recently questioned [25,26]. We found clear evidence for thepresence of both the mitochondrial and the cytoplasmic FH
isoforms in primary healthy human fibroblasts as well as in those
with RC deficiencies. However, the cytoplasmic FH was almost
completely lacking in all our FH-deficient lines, irrespective of
the underlying mutation. Intriguingly, mutations in any domain
of the yeast FH abolish export of themature cytoplasmic FH [27].
RC deficiency did not affect the FH isoform localization sug-
gesting that the mislocalization is not energy dependent. Our
finding can be explained either by translation-coupled transloca-
tion as in yeast, or decreased stability of the cytoplasmic defective
isoform. Therefore, all our FH-deficient cells lack the cytoplas-
mic enzyme activity almost completely, although residual acti-
vity remains in the mitochondria. Our finding emphasizes the
need for clarification of the function of the cytoplasmic isoform
and its relevance for FH-related pathogenesis.
FH and RC deficiencies shared some metabolic consequences,
such as upregulated glycolysis, but also had marked differences.
FH defect did not cause oxidative stress and the redox envi-
ronmentwas reduced,whereasRC defects resulted in activation of
oxidative stress defence. Fumarate increase has previously been
described to affect redox status, favoring GSH production [28],
but in our compound heterozygote cell lines, which also showed
high GSH, total fumarate concentration was similar to controls.
This suggested that fumarate alone was not responsible of the
observed redox change. However, by measuring the total cellular
fumarate, we cannot exclude local increases, or uneven distribu-
tion of the metabolite between cellular compartments. High cel-
lular GSH is typical for undifferentiated cell populations, such as
fetal tissues, stem cells and tumors [29,30], and has potential
to directly inhibit cellular differentiation (reviewed in [30,31]).
Smooth muscle homeostasis is maintained by stem cell differen-
tiation [32,33], and it is tempting to hypothesize that FH-deficient
smoothmuscle progenitor cells with reduced redox status could be
less prone to differentiate, increasing the likelihood of leiomyomas
in FH-deficient patients. Our results do not, however, explain the
tissue specificity. Our results do not support oxidative stress as a
prime inducer of FH-deficiency associated phenotypes.
Hypoxia-inducible factor-1α was not induced in any of our
FH- and RC-deficient fibroblasts. FH-deficient myomas have
been shown to have increased fumarate levels and HIF-1α
protein amounts, and therefore HIF-1α activation has been pro-
posed to underlie primary events of tumorigenesis in FH-
deficiency [10–12,14,17,19]. Fumarate, succinate, pyruvate,
oxaloacetate and other 2-oxoacids were also shown to promote
HIF-1α stabilization and accumulation [13,34–37], through in-
hibition of prolyl hydroxylase 2 [11,37,38]. Several studies using
cancer cells have shown accumulation of HIF-1α in response to
increased fumarate levels [34,36]. In our study, only those two
FH-deficient lines, which were homozygous for an active site
mutation, showed accumulation of fumarate, but even they did
not show HIF-1α activation. These data suggest that fumarate
accumulation does not always lead to HIF-1α activation but the
effect may be tissue-specific. The consequences of fumarate in
smooth muscle cell metabolism warrant further study.
In conclusion,we showhere that fumarate hydratase deficiency
results in a loss of cytoplasmic FH isoform and reduced cellular
redox state. Signalling functions ofmetabolites are only starting to
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and therefore also formed in the cytoplasm. Lack of cytoplasmic
FH could lead to local increase of cytoplasmic fumarate levels,
which could affect purinemetabolism, genome stability and tumor
formation in a redox environment favoring undifferentiated state.
Our data show that detailed studies on the role of cytoplasmic
FH and tissue-specific consequences of fumarate increase are
warranted to understand FH-associated tumorigenesis.
4. Materials and methods
4.1. Chemicals
Digitonin, GSSG,GSSG reductase, NADPH,NaN3, andN-dodecyl-maltoside
were from Sigma-Aldrich, Co. (St. Louis, Missouri, U.S.A.). GSH and NP-40
were from Fluka (Sigma-Aldrich). H2O2 (Perdrogen) was from Riedel-de-Haën
(Sigma-Aldrich). All chemicals were of the highest purity available.
4.2. Antibodies
Mouse monoclonal antibodies were used against HIF-1α (BD Biosciences,
San José, California, U.S.A.), β-actin (Sigma-Aldrich, Co.) and SDHA (Mole-
cular Probes, Invitrogen, Carlsbad, California, U.S.A.). Rabbit polyclonal anti-
bodies were used against FH (Nordic Immunology, Tillburg, The Netherlands).
Secondary antibodies horseradish-peroxidase-conjugated goat anti-mouse and
goat anti-rabbit were purchased from Molecular Probes.
4.3. Cell lines
Primary human fibroblasts were obtained by informed consent for research
purposes with approval from the Ethical Review Boards of the involved Uni-
versities. Four fumarate hydratase deficient fibroblast lines were used: FH-1,
homozygous for the E362Q mutation, with b1% remnant FH activity [40]; FH-2,
homozygous for the Q376P mutation, with b0.5% remnant FH activity [41];
FH-3, is a compound heterozygote with InsK477/R233H with ∼20% remnant
FH activity [42]; and FH-4, is a compound heterozygote with delV387 and
Q386H changes in one allele, and P369S in the other, with ∼5% remnant FH
activity [43]. Both mother and grand-mother of this child had uterine leiomyomas,
and paternal relatives had lung and laryngeal cancers [43]. The family members of
FH1-3 were not reported to have tumors at the time of examination, but follow-up
information was not available. The respiratory chain deficient lines were from an
18 year-old female patient with mitochondrial encephalomyopathy, lactic acidosis
and stroke-like-episodes syndrome (MELAS) due to a T3271Cmutation in tRNA-
leucine of mitochondrial DNA (mtDNA), with ∼80% of mutant mtDNA, and
from a 3 year-old patient with neurogenic muscle-weakness ataxia and retinitis
pigmentosa syndrome (NARP), due to the T8993C mutation in mtDNA with
∼90%mutant mtDNA.Control fibroblastswere from an adult, a child of 5months
and another of one year of age. None of the controls had an inherited disorder. FH-
4 line was available only for part of the studies due to technical reasons. Typical
passage numbers for the cells used in the studies were between ∼10 and 25.
4.4. Cell culture
Cells were cultured in Dulbecco's modified Eagle's medium with 4.5 g/l
glucose and 2 mM l-glutamine, supplemented with 10% fetal bovine serum,
uridine 50 µg/ml, penicillin 100 U/ml and streptomycin 100 µg/ml, at 37 °C in
the presence of 5% CO2. All cell culture reagents were from Gibco-Invitrogen
(Carlsbad, California).
4.5. Preparation of nuclear, mitochondrial, post-nuclear,
post-mitochondrial and whole cell extracts
Whole cell extracts: Primary fibroblast lines were trypsinized and pelleted at
800 ×g, 5 min. The cell pellets were suspended and washed once in phosphate-
buffered saline solution (PBS). For enzyme activity determination and mito-chondrial protein detection, the cell pellet was resuspended in n-dodecyl-malto-
side 1.5% (w/v) in PBS, supplemented with protease inhibitors (Complete
Protease inhibitor, Roche, Basel, Switzerland), incubated at 4 °C for 30 min with
rock-agitation, and centrifuged at 16,600 ×g for 20 min at 4 °C. The supernatant
(“whole cell extract”) was used immediately for protein quantification and
enzyme activity determination, or stored at −80 °C.
Mitochondrial extracts were prepared as described in [44], with slight mo-
difications. Briefly, cells were trypsinized, pelleted (800 ×g, 5 min) and washed
once in PBS. Cell pellet was resuspended in digitonin (0.8 mg digitonin in PBS/
mg protein), supplementedwith protease inhibitors (Complete Protease inhibitor,
Roche) and incubated for 5 min on ice. After dilution of samples with PBS,
suspensions were centrifuged at 10,000 ×g for 10 min at 4 °C. This supernatant
was the post-mitochondrial fraction, and the pellet contained enriched fraction of
mitochondria. The pellet was resuspended in 1% n-dodecyl-maltoside in PBS,
supplemented with protease inhibitors, incubated for 15 min on ice, and centri-
fuged at 20,000 ×g for 20min at 4 °C. The resulting supernatant was referred to as
mitochondrial extract. It was used immediately for protein quantification and
stored at −80 °C for protein detection.
Protein concentrations were measured at 595 nm, using Bio-Rad Protein
Assay (Bio-Rad, Hercules, California, U.S.A.), according to Bradford method.
4.6. Gel electrophoresis and Western blotting
Whole cell extracts,mitochondrial extracts or nuclear extractswere resolved by
SDS-PAGE on 7.5% (HIF-1α) or 10% (FH) Tris–glycine gels. Proteins were
blotted to PVDF (Immobilon-FL, Millipore Corporation, Bedford, MA, U.S.A.)
with a semi-dry transfer apparatus (Amersham Biosciences, GE Healthcare) with
25mMTris, 190mMglycine and 20%methanol.Membraneswere blocked for 1 h
at room temperature in 5% milk in TBST (20 mM Tris, 140 mM NaCl, 0,1%
Tween), and incubated with primary antibody (1:200, anti-HIF-1α; 1:200 anti-FH;
1:5000, anti-β-actin; 1:10,000 anti-SDHA) overnight at 4 °C. After washing in
TBST, membranes were incubated with horseradish-peroxidase-conjugated
secondary antibodies (Invitrogen; diluted in 5% milk in TBST; 1:4000 anti-
mouse for HIF-1α; 1:2000 anti-rabbit for FH; 1:5000 anti-mouse for β-actin;
1:5000 anti-mouse for SDHA) for 1 h at room temperature.As a positive control for
HIF-1α activation we utilized fibroblasts treated with 100 µM cobalt chloride for
4 h in regular cell culture conditions. Chemiluminescent detection was performed
using ECL Plus (Amersham Biosciences) or SuperSignal (Pierce, Rockford,
Illinois, U.S.A.) on X-Omat AR and X-Omat LS films (Kodak, Hemel, United
Kingdom), or detected with Typhoon fluorescence scanner (GE Biosciences), and
the signal was quantified utilizing Image-Quant software (GE Biosciences).
4.7. Metabolite extraction and analysis
The cells were collected in equal confluency, by trypsinization, pelleted
(800 ×g, 5 min), washed once in PBS and the pellet (800 ×g, 5 min) was frozen at
−80 °C until extraction. The cell pellet was suspended in 2.5 ml of boiling 80%
(w/w) ethanol and heated for 3min in a boilingwater bath. The sampleswere then
centrifuged and the supernatant recovered. Pellets contained the macromolecules
of the cells and were discarded. The supernatants were evaporated in a vacuum
drier (SpeedVac). The dry samplewas dissolved in 200 µl of deionizedwater. The
solution was filtered through a 0.45 µm-membrane centrifugal filter at 12,000 g
for 5 min. The filtrate with the metabolites was then analyzed by anion exchange
liquid chromatography with tandem mass spectrometric detection. The LC-MS
analysis method was a modification of the method described in [45]. Metabolites
analyzed were malate, fumarate, α-ketoglutarate, succinate, citrate/isocitrate,
pyruvate, 2-phospho-glycerate/3-phospho-glycerate, glucose-1-phosphate, phos-
phoenolpyruvate and glyceraldehyde-3-phosphate.
4.8. Quantitative PCR
Total RNA was extracted from fresh cell pellets using RNeasy mini RNA
extraction kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's
instructions. cDNAwas synthesized using M-MLV polymerase according to the
manufacturer's instructions, with random RNA hexamer primers (Roche). Real-
time quantitative amplification was carried out using TaqMan system according
to the manufacturer's protocol, with standardized Assays-on-Demand probes
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with AbiPrism (Applied Biosystems) and the cDNA levels were determined at
the exponential phase of PCR reaction, with the ABI7000 software (Applied
Biosystems).
4.9. Glutathione and cysteine concentration
The thiol metabolism was evaluated by measuring the total and free glu-
tathione levels as previously described [46]. In brief, free sulfhydryls of thiols
were derivatized with monobromobimane to form fluorescent complexes. The
derivatized thiols were then separated by high-performance liquid chromato-
graphy (HPLC) and quantified by fluorimetry. In order to measure the total
(reduced+oxidized) concentration of glutathione or cysteine, aliquots of the
samples were first treated with 10 μM dithiothreitol to reduce disulphides.
Another aliquot was immediately treated with 15% (w/v) sulfo-salicylic acid to
precipitate proteins. This allows separation of small-molecule mixed disulphides
from larger complexes, such as protein-glutathione.
4.10. Enzyme activity measurements
Enzyme activities were determined in whole cell extracts. Glutathione
peroxidase (GPx) assay followed the consumption of NADPH by the coupled
reaction of glutathione reductase at 340 nm, using H2O2 as substrate [47]. GPx
activity unit corresponded to the formation of 1 μmol GSSG/min/mg protein.
Glutathione reductase (GR) assay followed the consumption of NADPH at
340 nm [28]. GR activity unit corresponded to the consumption of 1 μmol
GSSG/min/mg protein. Catalase activity assay followed the consumption of
H2O2 at 240 nm, at pH 7.0. Catalase activity unit corresponded to 1 μmol H2O2
consumed/min/mg protein.
4.11. Analysis of H2O2 concentration
Cells were seeded at the density of 5000 cells/well in 96-well plates and
allowed to attach overnight. The wells were washed with PBS and replaced with
normal culture medium. Background fluorescence (excitation 485 nm, emission
530 nm)wasmeasured using amicroplate fluorescence reader (Plate Chameleon,
Hidex, Turku, Finland). Normal medium was replaced with medium containing
50 μM dichlorofluorescein diacetate (DCFH-DA, Molecular Probes) and 0.1%
dimethylsulphoxide (DMSO) or, as control, normal medium containing 0.1%
DMSO, and incubated at 37 °C, for 30 min in the cell incubator. Cells were then
washed once with PBS, and normal mediumwas added. DCFH fluorescence was
measured. Background and DCFH fluorescence were normalized against control
wells. As a positive control, some cells were treated with 10 mMH2O2 for 5 min
at 37 °C after DCFH was removed, and then DCFH fluorescence was measured.
DCFH oxidation is driven mostly by H2O2 in the cellular context, although
reactionwith other oxidants, such as peroxynitrite, can contribute in a low level to
the signal [48].
4.12. Cell proliferation assay
Primary fibroblasts were plated in luminescence-compatible 96-well plates
(500 cells/well). The cell number was estimated using ViaLight HS proliferation
assay (Cambrex BioScience Rockland, Charles City, Iowa, U.S.A.). The cells
were allowed to attach, after which the first measurement was performed (point
zero). Further measurements were made 1, 3, 5 and 9 days after plating. Each
cell line in each time point was normalized to its own point zero, since somewhat
decreased ATP production could be expected in the mitochondrial disease lines.
The growth rates of the different patient lines were compared to the controls. The
cells used for the proliferation assay were in passage numbers ( p): control 1
( p=18), control 2 ( p=34), control 3 ( p=21), FH-1 ( p=23), FH-2 ( p=23), FH-
3 ( p=20), MELAS ( p=18) and NARP ( p=10).
4.13. Statistical analysis
The number of independent replicates per experiment was typically five.
Each patient cell line was compared to the pooled controls using Student's t-testfor two-tailed distributions with unequal variance. P-values under 0.05 were
considered significant.
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